Omnicell (NASDAQ:OMCL – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.
Analyst Ratings
This is a summary of current recommendations for Omnicell and KORU Medical Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Omnicell | 1 | 1 | 7 | 0 | 2.67 |
| KORU Medical Systems | 1 | 0 | 4 | 0 | 2.60 |
Omnicell presently has a consensus target price of $57.86, suggesting a potential upside of 55.82%. KORU Medical Systems has a consensus target price of $7.00, suggesting a potential upside of 112.12%. Given KORU Medical Systems’ higher possible upside, analysts plainly believe KORU Medical Systems is more favorable than Omnicell.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Omnicell | 3.13% | 5.66% | 3.57% |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
Insider & Institutional Ownership
97.7% of Omnicell shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Omnicell and KORU Medical Systems”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Omnicell | $1.18 billion | 1.43 | $2.05 million | $0.84 | 44.20 |
| KORU Medical Systems | $41.13 million | 3.69 | -$2.64 million | ($0.04) | -82.50 |
Omnicell has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Omnicell has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Summary
Omnicell beats KORU Medical Systems on 11 of the 14 factors compared between the two stocks.
About Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
